ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $105.57 Consensus Price Target from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $105.5714.

A number of analysts recently weighed in on the stock. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Canaccord Genuity Group lowered their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Guggenheim cut their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Finally, Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 target price on the stock.

Insiders Place Their Bets

In related news, SVP Ori Gutwerg sold 3,162 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $77.00, for a total value of $243,474.00. Following the completion of the sale, the senior vice president owned 75,534 shares in the company, valued at $5,816,118. This represents a 4.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jeanne Thoma sold 1,000 shares of ANI Pharmaceuticals stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $71.53, for a total value of $71,530.00. Following the transaction, the director owned 26,762 shares in the company, valued at approximately $1,914,285.86. This represents a 3.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,925 shares of company stock worth $1,794,295 over the last 90 days. 8.10% of the stock is currently owned by corporate insiders.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Penn Capital Management Company LLC boosted its holdings in ANI Pharmaceuticals by 2,058.9% during the fourth quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock worth $10,858,000 after purchasing an additional 131,030 shares during the last quarter. CenterBook Partners LP acquired a new stake in ANI Pharmaceuticals in the 4th quarter valued at $1,518,000. Jupiter Topco LLC acquired a new stake in ANI Pharmaceuticals in the 2nd quarter valued at $6,597,000. NFJ Investment Group LLC bought a new stake in ANI Pharmaceuticals during the 2nd quarter worth about $2,766,000. Finally, Walleye Capital LLC bought a new stake in ANI Pharmaceuticals during the 2nd quarter worth about $8,784,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Trading Up 2.4%

NASDAQ ANIP opened at $72.11 on Friday. The stock has a 50-day simple moving average of $76.69 and a 200 day simple moving average of $78.14. The company has a market capitalization of $1.66 billion, a PE ratio of 15.54 and a beta of 0.45. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals has a 12 month low of $69.58 and a 12 month high of $99.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The firm had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company’s revenue was up 25.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts forecast that ANI Pharmaceuticals will post 7.83 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.